 Connection
Rama Kant to Prostatic Neoplasms
This is a "connection" page, showing publications Rama Kant has written about Prostatic Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.453 |
|
|
|
-
Tomar MS, Raina K, Mishra N, Kant R, Fox JT, Agarwal C, Agarwal R. Distinct Tumor Infiltrating Immune Cell Profiles in Mice by Non-Steroidal Anti-Inflammatory Drugs (Aspirin and Naproxen) During TMPRSS2-ERG (Fusion)-Driven and Non-Fusion Driven Prostate Cancer. Mol Carcinog. 2026 May; 65(5):589-602.
Score: 0.140
-
Prasad RR, Mishra N, Kant R, Fox JT, Shoemaker RH, Agarwal C, Raina K, Agarwal R. Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis. Mol Carcinog. 2024 Jun; 63(6):1188-1204.
Score: 0.123
-
Raina K, Kant R, Prasad RR, Kandhari K, Tomar M, Mishra N, Kumar R, Fox JT, Sei S, Shoemaker RH, Chen Y, Maroni P, Agarwal C, Agarwal R. Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models. Mol Carcinog. 2022 07; 61(7):717-734.
Score: 0.107
-
da Silva RF, Dhar D, Raina K, Kumar D, Kant R, Cagnon VHA, Agarwal C, Agarwal R. Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators. Sci Rep. 2018 06 22; 8(1):9540.
Score: 0.082
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|